Phaseline

Targets › BCHE

BCHE (Cholinesterase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Other; next expected readout Nov 2028.

Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. (UniProt, P06276)

Open in Phaseline: the race on BCHE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Washington University School of MedicineRivastigmine
Cholinesterases; ACHE & BCHE inhibitor
BCHE, ACHEPhase 2Anticholinergic ToxicityNov 2028

Conditions

Anticholinergic Toxicity (1)

Modalities

small molecule (1)

Companies

Washington University School of Medicine (1)

Related targets

ACHE (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.